Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?

Carlos L. Arteaga, Jose Baselga

Research output: Contribution to journalReview article

85 Citations (Scopus)

Abstract

The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)525-531
Number of pages7
JournalCancer Cell
Volume5
Issue number6
DOIs
StatePublished - Jun 1 2004

Fingerprint

Protein-Tyrosine Kinases
Gastrointestinal Stromal Tumors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Epidermal Growth Factor Receptor
Patient Selection
Breast Neoplasms
Neoplasms
Therapeutics
Imatinib Mesylate
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Tyrosine kinase inhibitors : Why does the current process of clinical development not apply to them? / Arteaga, Carlos L.; Baselga, Jose.

In: Cancer Cell, Vol. 5, No. 6, 01.06.2004, p. 525-531.

Research output: Contribution to journalReview article

@article{d9f9fed2f8f7440f9672ec306c6b9eba,
title = "Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?",
abstract = "The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.",
author = "Arteaga, {Carlos L.} and Jose Baselga",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.ccr.2004.05.028",
language = "English (US)",
volume = "5",
pages = "525--531",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors

T2 - Why does the current process of clinical development not apply to them?

AU - Arteaga, Carlos L.

AU - Baselga, Jose

PY - 2004/6/1

Y1 - 2004/6/1

N2 - The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.

AB - The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.

UR - http://www.scopus.com/inward/record.url?scp=2942603264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942603264&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2004.05.028

DO - 10.1016/j.ccr.2004.05.028

M3 - Review article

C2 - 15193255

AN - SCOPUS:2942603264

VL - 5

SP - 525

EP - 531

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -